Inspire Medical Systems is a medical device company focused on developing innovative solutions to treat obstructive sleep apnea
The company specializes in the design and manufacturing of implantable neurostimulation devices that work to improve airflow during sleep by stimulating the hypoglossal nerve, which helps keep the airway open. Their technology aims to provide an effective alternative for individuals who are unable to tolerate traditional continuous positive airway pressure (CPAP) therapy. Through its pioneering approach, Inspire Medical Systems is committed to enhancing the quality of life for patients with sleep-disordered breathing conditions.
Looking back on medical devices & supplies - specialty stocks’ Q4 earnings, we examine this quarter’s best and worst performers, including Globus Medical (NYSEGMED) and its peers.
Many small-cap stocks have limited Wall Street coverage, giving savvy investors the chance to act before everyone else catches on.
But the flip side is that these businesses have increased downside risk because they lack the scale and staying power of their larger competitors.
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at STAAR Surgical (NASDAQSTAA) and the best and worst performers in the medical devices & supplies - specialty industry.
Since August 2024, Inspire Medical Systems has been in a holding pattern, posting a small loss of 2.8% while floating around $183.55. The stock also fell short of the S&P 500’s 6.1% gain during that period.
Medical technology company Inspire Medical Systems (NYSEINSP) reported Q4 CY2024 results topping the market’s revenue expectations, with sales up 24.5% year on year to $239.7 million. The company expects the full year’s revenue to be around $947.5 million, close to analysts’ estimates. Its GAAP profit of $1.15 per share was 54% above analysts’ consensus estimates.
BofA upgrades Inspire Medical to Buy, setting a $255 price target. The company aims for $950 million in 2025 revenue, with a focus on new product launches and expansion.
